Bioheng Biotech Received Orphan Drug Designation from the US FDA for the Treatment of T-ALL

Nanjing Bioheng Biotech Co., Ltd. announced UCAR T cell therapy product targeting CD7, received Orphan Drug Designation from the US FDA for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).